Antibiotic treatment for urinary tract infections: Pharmacokinetic/pharmacodynamic principles

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 6, 2004, Pages 923-931

  Wagenlehner, Florian M E ^a   Naber, Kurt G ^a  

^a Urologische Klinik   (Germany)

Author keywords

Antibiotic resistance of uropathogens; Antibiotic treatment; Complicated infections; Dosing of antibiotics; Spectrum of uropathogens; Uncomplicated infections; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFEPIME; CEFOTAXIME; CEFOTIAM; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; COTRIMOXAZOLE; ENOXACIN; ERTAPENEM; FOSFOMYCIN TROMETAMOL; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; UNINDEXED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; INDIVIDUALIZATION; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OUTPATIENT; PATIENT CARE; PREVALENCE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS SAPROPHYTICUS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 9944224181     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.6.923     Document Type: Review

References (45)

1. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 29, 745-758 (1999).
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113(Suppl. 1A), S5-S13 (2002).
3. Gales AC, Jones RN, Gordon KA et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J. Antimicrob. Chemother. 45, 295-303 (2000).
4. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J. Urol. 168, 1720-1722 (2002).
5. Rüden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP). Infection 25, 199-202 (1997).
6. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. Emerg. Infect. Dis. 7, 1-6 (2001).
7. Patton JP, Nash DB, Abrutyn E. Urinary tract infection: economic considerations. Med. Clin. North Am. 75, 495-513 (1991).
8. Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am. J. Med. Sci. 314, 245-249 (1997).
9. Hooton TM. The current management strategies for community acquired urinary tract infection. Infect. Dis. Clin. North Am. 17, 303-332 (2003).
10. Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N. Engl. J. Med. 349, 259-266 (2003).
11. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncompicated urinary tract infections: The ECO.SENS project. J. Antimicrob. Chemother. 51, 69-76 (2003).
12. Wagenlehner FME, Niemetz A, Dalhoff A, Naber KG. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000. Int. J. Antimicrob. Agents 19, 557-564 (2002).
13. Hisanaga TL, Decorby MR, Laingk NM et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 9-12 October 2003 (Abstract 226).
14. Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 45, 295-301 (2000).
15. Roberts WO (Ed.). A special report. Urinary tract infections and the cost of antimicrobial resistance: focus on acute uncomplicated cystitis. Postgrad. Med. (2001).
16. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial resistance among urinary tract infection (UTIs) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Antonie Van Leeuwenhoek 77, 147-152 (2000).
17. Drusano GL, Preston SL, Hardalo C et al. Use of preclinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45, 13-22 (2001).
18. Costerton JW. Introduction to biofilm. Int. J. Antimicrob. Agents 11, 217-221 (1999).
19. Reid G. Biofilms in infectious disease and on medical devices. Int. J. Antimicrob. Agents 22, 223-226 (1999).
20. Goto T, Nakame Y, Nishida M, Ohi Y. Bacterial biofilms and catheters in experimental urinary tract infection. Int. J. Antimicrob. Agents. 11, 227-231 (1999).
21. Tsukamoto T, Matsukawa M, Sano M et al. Biofilm in complicated urinary tract infection. Int. J. Antimicrob. Agents 11, 233-236 (1999).
22. Pea F, Pavan F, Di Qual E et al. Urinary pharmacokinetics and theoretical phannacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. J. Chemother. 15, 563-567 (2003).
23. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the missuse of culture results and antibiotic sensitivities in patients with community acquired bacteremia due to urinary tract infection. J. Infect. 35, 283-288 (1997).
24. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69, 4572-4579 (2001).
25. Iványi B, Rumpelt HJ, Thoenes W. Acute human pyelonephritis: leukocytic infiltration of tubules and localization of bacteria. Virchows Archintravenously A. Pathol. Anat. 414, 29-37 (1988).
26. Deguchi T, Kuriyama M, Maeda S et al. Electron microscopic study of acute retrograde pyelonephritis in mice. Urology 35, 423-427 (1990).
27. Chippendale GR, Warren JW, Trifillis AL, Mobley HLT. Internalization of Proteus mirabilis by human renal epithelial cells. Infect. Immun. 62, 3115-3121 (1994).
28. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int. J. Antimicrob. Agents 19, 546-553 (2002).
29. Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rsanmussen SN, Frimodt-Møller N. Development of a long-term ascending uirinary tract infection mouse model for antibiotic treatment studies. Antimicrob. Agents Chemother. 44, 156-163 (2000).
30. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int. J. Antimicrob. Agents 17, 331-341 (2001).
31. Boy D, Well M, Kinzig-Schippers M, Sörgel F, Ankel-Fuchs D, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int. J. Antimicrob. Agents 23(Suppl. 1), 6-16 (2004).
32. Naber KG, Fünfstück R, Hofstetter A, Brühl P, Hoyme U. Empfehlungen zur antimikrobiellen therapie von infektionen der nieren und des urogenitaltraktes bei erwachsenen. Chemother. J. 9, 193-199 (2000).
33. Naber KG, Bergman B, Bishop MC et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Healthcare Office (HCO) of the European Association of Urology (EAU). Eur. Urol. 40, 576-588 (2001).
34. Bailey RR, Peddie BA, Bishop V. Comparison of single dose with 5-day course of trimethoprim for asymptomatic (covert) bacteriuria of pregnancy. N. Zealand Med. J. 99, 501-503 (1986).
35. Österberg E, Åberg H, Hallander HO, Kallner A, Lundin A. Efficacy of single-dose versus 7-day trimethoprim treatment of cystitis in women: a randomized double-blind study. J. Infect. Dis. 161, 942-947 (1990).
36. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin. Infect. Dis. 34, 1061-1066 (2002).
37. Drlica K. A strategy for fighting antibiotic resistance. ASM News 67, 27-33 (2001).
38. Kavatha D, Giamarellou H, Alexiou Z et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob. Agents Chemother. 47, 897-900 (2003).
39. Talan DA, Stamm WE, Hooton TM et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. J. Am. Med. Assoc. 283, 1583-1590 (2000).
40. Braveny I, Maschmeyer G. Infektionskrankheiten. In: Diagnostik Klinik Therapie. Medco, Munich, Germany (2002).
41. Vogel F, Naber KG, Wacha H et al., und eine expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Parenterale antibiotika bei erwachsenen. Chemother. J. 8(1), 2-49 (1999).
42. Naber KG, Adam D, und eine expertengruppe der Paul-Elirlich-Gesellschaft für Chemotherapie e.V. Einteilung der fluorchinolone. Chemother. J. 7(2), 66-68 (1998).
43. Geerlings SE, Stolk RP, Camps MJL et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabet. Care 23, 744-749 (2000).
44. Meiland R, Geerlings SE, Hoepelman AI. Management of bacterial urinary tract infections in adult patients with diabetes mellitus. Drugs 62, 1859-1868 (2002).
45. Naber KG, Fünfstück R, Gatermann S, Hoyme U. Infektionen der Nieren und des Urogenitaltraktes. Chemother. J. 13, 78-84 (2004).